Experimental gene therapy found to slow Huntington’s disease progression, company says

UniQure's experimental gene therapy, AMT-130, demonstrated a 75% slowdown in Huntington's disease progression over 36 months in a pivotal Phase 1/2 study, alongside a manageable safety profile and an 8.2% reduction in neurofilament light protein. This marks a significant advance toward a potential first genetic treatment for the rare neurodegenerative condition, with the company targeting a Q1 2026 FDA submission and a potential late 2026 launch. While promising, the early-stage data, based on a modest patient cohort and some historical controls, will require further validation for full market confidence.

Analysis

UniQure (QURE) has reported highly promising pivotal Phase 1/2 study results for its experimental gene therapy, AMT-130, for Huntington's disease. The data shows a significant 75% slowdown in disease progression at 36 months for patients receiving a high dose, a potentially transformative outcome for a condition with no existing disease-modifying treatments. This clinical finding is supported by a key biomarker, with an average 8.2% reduction in cerebrospinal neurofilament light protein, indicating a decrease in neurodegeneration. UniQure has outlined a clear regulatory pathway, targeting a US FDA submission in the first quarter of 2026, which could position the therapy for a late 2026 launch. While the treatment's safety profile was described as "manageable," it is crucial to note the study's limitations. The trial involved a modest number of patients, and the full data has not yet been peer-reviewed. Furthermore, external experts highlight that control data was partially derived from existing natural history data rather than a dedicated placebo group, and the lack of reported data for the low-dose group suggests it was likely ineffective, concentrating the therapy's success solely on the high-dose cohort.

Key Decisions for Investors

• The highly positive efficacy data for AMT-130 in a high-unmet-need indication presents a compelling long-term catalyst for UniQure, warranting consideration for investors with a high tolerance for clinical-stage biotech risk.
• Investors should closely monitor for the full peer-reviewed publication of the study data to scrutinize the trial's methodology, particularly the use of historical controls and the full safety profile, as these will be key to de-risking the asset.
• The Q1 2026 FDA submission target is the next major milestone; any communication from the company regarding regulatory feedback or further data readouts will be critical drivers of valuation leading up to this event.